Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Authors :: Hun Ju Lee
Jeremy S. Abramson
Nancy L. Bartlett
John M. Burke
Ryan C. Lynch
Domingo Domenech Eva
Brian T. Hess
Steven R. Schuster
Yuliya Linhares
Rod Ramchandren
Mitul Gandhi
Rex Mowat
Harsh Shah
Giuseppe Rossi
Uwe H Hahn
Henry Miles Prince
Linda Ho
Wenchuan Guo
Christopher A. Yasenchak
David J. Straus
Source :: Blood. 140:9399-9401
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools